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Abstract
Risk assessment for natalizumab-associated progressive multifocal leukoencephalopathy (Nat-PML)
comprises the anti-JC virus (JCV) antibody index (AI). The anti-JCV AI was longitudinally determined
in a natalizumab-treated MS cohort (Nat-MS, n¼ 468) and samples of Nat-PML patients (n¼ 15). In
Nat-MS, the median AI was 0.8 (25th to 75th percentile, 0.22.8) with an intra-individual coefficient of
variation (CV) of 9.8% (4.817.6). Patients with an AI 0.9 exhibited higher CV. The AI was higher
(3.4 (3.13.6)) in samples before Nat-PML diagnosis than in seropositive Nat-MS (2.4 (1.03.4),
n¼ 298, p¼ 0.010). AIs 3.0 were associated with a 14.5-fold (95% CI 2.390.4) increased PML risk
(p¼ 0.002). Groups with an AI below 1.5 exhibit higher variability or even serostatus fluctuation.
AI dynamics require further investigation.
Keywords: Multiple sclerosis, natalizumab, PML, biomarker
Introduction
Treatment of Multiple sclerosis (MS) with natalizu-
mab (Nat) is associated with progressive multifocal
leukoencephalopathy (PML). The presence of anti-
bodies against the causative JC virus (JCV) increases
the risk to develop Nat-associated PML (Nat-PML).1
The level of antibody reactivity is proposed to refine
this risk in patients without prior immunosuppressive
treatment.24 Although one study suggested increas-
ing antibody reactivity towards Nat-PML diagnosis,5
persistently high anti-JCV antibody indices (AIs)
prior to diagnosis have been reported.2,6 We examine
longitudinal variation of anti-JCV AIs in an inde-
pendent large German cohort of natalizumab-treated
MS patients and in the context of Nat-PML and PML
of different etiology.
Methods
Ethics approval was obtained (Ruhr-University
Bochum, registration-no. 3814-10). The anti-JCV
AI was retrospectively determined by STRATIFY
JCVTM DxSelectTM,7 in the following cohorts: a lon-
gitudinal cohort of Nat-treated MS patients in the
post-marketing setting (Nat-MS, n¼ 468, Table 1);
Nat-PML patients (n¼ 15, Table 2); patients with
PML of other etiology (lymphoma: n¼ 2; HIV:
n¼ 1; Fumaderm treatment8: n¼ 1; Table 3, all
PML diagnosed according to ref. 9).
Clinical data of 10/15 Nat-PML patients (Table 2,
patients 110) were presented in our previous
study;3 4/15 (patients 2, 68) were included in a pre-
vious study2. Samples were available prior to Nat-
PML (n¼ 9 patients) and longitudinally (before/at/
after PML-diagnosis, n¼ 8 patients, Table 2). Of the
multiple samples taken before PML diagnosis, the ear-
liest was included in the cross-sectional analyses.
Statistical analyses were performed using SPSS
22 with p-values< 0.05 considered significant.
Data are presented as median (25th to 75th percent-
ile) or (95% confidence interval (CI)). Odds ratios
(ORs) of the CI were calculated with the
CoxHinkleyMiettinenNurminen method.
Results
Nat-MS cohort
63.7% (n¼ 298) were anti-JCV seropositive at first
sampling. Irrespective of serostatus, the anti-JCV AI
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showed modest fluctuation over time: intra-indivi-
dual coefficient of variation (CV) 9.8% (4.817.6);
median AIs of 0.8 (0.22.8) at first, 0.9 (0.22.8) at
second time point. Initially seropositive patients
exhibited an AI of 2.4 (1.03.4) at first testing
with a CV of 7.7% (3.715.3). Eight of 298 sero-
positive patients had no AI change, 113/298 an AI
increase, and 177/298 an AI decrease.
Stratified by AI thresholds,2 groups with lower AIs
demonstrated higher CV (AI 0.4 (n¼ 193): CV
12.9% (6.722.6); AI> 0.4 0.9 (n¼ 45): CV
15.5% (8.126.2) versus AI> 1.5 3.0 (n¼ 95):
CV 9.4% (4.215.2); AI> 3.0 (n¼ 103): CV 4.6%
(2.47.8)). A significant difference in CV was also
observed between AI groups> 0.9 1.5 (n¼ 32,
CV 12.2% (4.327.1)) versus >3.0 and >1.5
 3.0 versus >3.0 (all p< 0.001, KruskalWallis/
Dunn’s post hoc test, no differences in sampling
intervals, Figure S1 (available online)).
Serostatus change from negative (36.3% at first time
point) to positive was observed in 11% over 7.6
(4.612.2) months. Twelve of 19 exhibited an
AI 0.9 at second testing. The fastest seroconver-
sion from negative to positive with an AI increase
of 2.0 was observed over 1.8 months; a maximum AI
increase from 0.1 to 3.5 was seen within 11.8
months.
Serostatus change from positive (63.7% at first time
point) to negative occurred in 4% over 4.6 (2.87.1)
months. The highest initial AI in this subgroup was
0.83. In 9/12 patients, confirmatory testing deter-
mined seronegative status at second testing.
Despite high CV of 33.3% (19.888.4) in patients
with change in serostatus (n¼ 31), AIs remained low
(first AI 0.3 (0.20.4); second AI 0.4 (0.30.7)).
Seropositive patients were older than seronegative
patients (39.3 (31.145.2), n¼ 297, versus 36.1
(28.942.9), n¼ 168, p¼ 0.005, MannWhitney
test, two-sided). Gender, pre-treatment groups (com-
prising any pre-treatment prior to initiation of Nat (i.e.
immunomodulators and immunosuppressants),
immunomodulators, immunosuppressants including
mitoxantrone, mitoxantrone alone), anti-Nat antibody
status were neither associated with serostatus (Table
1) nor anti-JCV AI in seropositive patients (Figure 1).
PML cohorts
Nat-PML and PML patients of other etiology tested
seropositive at all time points (Tables 2 and 3). In
samples 26.3 (19.234.5) months before Nat-PMLT
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(n¼ 9), the AI was higher (3.4 (3.13.6)) than in
seropositive Nat-MS (2.4 (1.03.4), n¼ 298,
p¼ 0.010, MannWhitney test, two-sided). The AI
before occurrence of Nat-PML was 3.0 in eight out
of nine patients resulting in a 14.5 higher (95% CI
2.390.4) PML risk with an AI threshold dichoto-
mized as 3.0 versus <3.0 (p¼ 0.002, Fisher’s exact
test, two-sided). The lowest AI threshold with
increased PML risk was 2.2 (OR 6.9 (95% CI
1.142.0); p¼ 0.044).
Longitudinal Nat-PML samples demonstrated persist-
ently high AIs3.0. AIs remained3.0 in all but one
sample at/after Nat-PML diagnosis (Table 2). PML of
other etiology exhibited an AI of 3.7 (1.23.9) around
time point of diagnosis (Table 3).
Discussion
Seroprevalence in this Nat-MS cohort was higher
(63.7%) than in other studies3,5,6,10 but proportions
of patients with serostatus change were similar.3,5
Seropositivity was consistently associated with
age.3,10 Significant associations of AI levels with
age, gender, pre-treatment, and anti-Nat antibodies
within the seropositive cohort were absent.
AI levels in our seropositive Nat-MS patients are
higher than in the initial report2, but similar to a
more recent study.6 The reasons are not clear; our
cohort and the latter with open-label treatment in
different clinical settings may reflect an unbiased,
mixed collective.
Of note, variation of anti-JCV AI is common, with
only eight out of 298 seropositive patients exhibiting
no AI change at all. Yet, there are differences in the
magnitude of variability. Stratified by anti-JCV AI,
groups with low AI (0.4; >0.40.9) exhibited
higher variability partially leading to change in
serostatus despite advances of the second gen-
eration assay6,7. Especially in these subgroups, deter-
mination of serostatus may be less predictive than
absolute AI level to determine low PML-risk.
The lowest AI variability was seen in AI-groups
>1.53.0 and >3.0; however, for AIs above 2.5
the assay signal is saturated, partially explaining
lower CV in high AI groups.
As an AI threshold of 1.5 versus >1.5 is proposed
to provide a conservative risk estimate2, evaluation
of AI fluctuation in the group of >1.53.0 may
help to refine PML risk assessment: individual
dynamics of anti-JCV AI exceeding the projected
inter-test variability defined as more than twofold
median CV in this group, i.e. 18.8%, may point to
an underlying biological process.
The lowest anti-JCV AI in samples prior to PML
diagnosis was 1.8; high anti-JCV AIs were thus con-
sistently detected in Nat-PML including samples up
to 3 years prior to Nat-PML diagnosis in line with
other studies2,6 without an increase of antibody
reactivity towards PML diagnosis5.
Owing to the retrospective character, we were only
able to include JCV DNA findings in serum/CSF of
some PML patients impairing conclusions on poten-
tial relationships between AI and viral load.
In our cohorts, an AI 3.0 was associated with a
14.5-fold PML risk. However, an exact threshold
Table 3. Demographic and clinical characteristics of patients with PML of different etiology.
Case no. 1 2 3 4
PML etiology Fumaderm HIV lymphoma lymphoma
Sex M M M M
Age at PML-diagnosis, y 69 45 64 56
Sample collection in relation
to PML-diagnosis, m
0.5 0 3.8 0
Immunosuppressive pre-treatment no no yes yes
AI 3.6 3.9 1.2 3.8
JCV DNA, copies per ml (CSF)1 16 2400 neg2 4125
JCV DNA, copies per ml (s)1 neg n/a n/a n/a
1Collected at the time point of diagnosis, if not indicated otherwise. 24 months after diagnosis. AI: antibody index;
CSF: cerebrospinal fluid; DNA: deoxyribonucleic acid; HIV: human immunodeficiency virus; JCV: John Cunningham
virus; m: months; M: male; n/a: not available; neg: negative; PML: progressive multifocal leukoencephalopathy; s:
serum; y: years
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remains unclear taking into account higher AIs in
comparison with previous observations2 and the
small number of samples before PML diagnosis
(n¼ 9) in our study. Still, even a more conservative
threshold, e.g., at an AI level of 1.5,2 can only reflect
statistical risk estimations that need to be combined
with individual risk-assessment.
Whether determination of AI dynamics, especially in
AIs> 1.5, may be additionally helpful in PML risk
assessment, deserves further investigation in a pro-
spective setting. Our study supports repeated deter-
mination of anti-JCV-AI in addition to serostatus in
Nat-PML risk stratification.
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